PHAXIAM THERAPEUTICS S.A. PHAXIAM Therapeutics S.A. Euronext Paris
Equities
PHXM
FR0011471135
Biotechnology & Medical Research
|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.91 EUR | -1.02% |
|
-0.85% | -36.74% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
2024-05-14
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.94
EUR
Average target price
6.85
EUR
Spread / Average Target
+132.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.71% | 103B | |
| +2.49% | 96.73B | |
| 0.00% | 21.31B | |
| -16.61% | 21.21B | |
| -6.45% | 18.79B | |
| -42.14% | 16.37B | |
| -27.40% | 13.68B | |
| +1.44% | 13.44B | |
| +21.29% | 10.98B |
- Stock Market
- Equities
- PHXM Stock
- PHXM Stock
- News PHAXIAM Therapeutics S.A.
- Erytech Secures US Patent For Red Blood Cell Platform's Use In Rare Metabolic Diseases
